226 related articles for article (PubMed ID: 22464691)
21. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
[TBL] [Abstract][Full Text] [Related]
23. Adherence to premixed insulin in a prefilled pen compared with a vial/syringe in people with diabetes in Singapore.
Cheen HH; Lim SH; Huang MC; Bee YM; Wee HL
Clin Ther; 2014 Jul; 36(7):1043-53. PubMed ID: 24913030
[TBL] [Abstract][Full Text] [Related]
24. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe.
Baser O; Bouchard J; DeLuzio T; Henk H; Aagren M
Adv Ther; 2010 Feb; 27(2):94-104. PubMed ID: 20352392
[TBL] [Abstract][Full Text] [Related]
25. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus.
Xie L; Zhou S; Wei W; Gill J; Pan C; Baser O
Diabetes Technol Ther; 2013 Mar; 15(3):230-6. PubMed ID: 23336845
[TBL] [Abstract][Full Text] [Related]
26. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
27. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
28. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Bergeson JG; Worley K; Louder A; Ward M; Graham J
J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
[TBL] [Abstract][Full Text] [Related]
29. Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Naïve Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes.
Slabaugh SL; Bouchard JR; Li Y; Baltz JC; Meah YA; Moretz DC
Adv Ther; 2015 Dec; 32(12):1206-21. PubMed ID: 26563324
[TBL] [Abstract][Full Text] [Related]
30. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
31. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID.
Baser O; Wei W; Baser E; Xie L
J Med Econ; 2011; 14(6):673-80. PubMed ID: 21892858
[TBL] [Abstract][Full Text] [Related]
32. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
[TBL] [Abstract][Full Text] [Related]
33. Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen.
Gundgaard J; Christensen TE; Thomsen TL
Prim Care Diabetes; 2010 Oct; 4(3):165-72. PubMed ID: 20452847
[TBL] [Abstract][Full Text] [Related]
34. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
35. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
Malmenäs M; Bouchard JR; Langer J
Clin Ther; 2013 Jun; 35(6):795-807. PubMed ID: 23642290
[TBL] [Abstract][Full Text] [Related]
36. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
Eby EL; Boye KS; Lage MJ
J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
[TBL] [Abstract][Full Text] [Related]
37. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.
Perez-Nieves M; Kabul S; Desai U; Ivanova JI; Kirson NY; Cummings AK; Birnbaum HG; Duan R; Cao D; Hadjiyianni I
Curr Med Res Opin; 2016; 32(4):669-80. PubMed ID: 26703951
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting.
Davis SN; Wei W; Garg S
Endocr Pract; 2011; 17(6):845-52. PubMed ID: 21550952
[TBL] [Abstract][Full Text] [Related]
39. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
Sheffield CA; Kane MP; Busch RS
Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
[TBL] [Abstract][Full Text] [Related]
40. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.
Cheong C; Barner JC; Lawson KA; Johnsrud MT
Clin Ther; 2008 Oct; 30(10):1893-907. PubMed ID: 19014846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
